Tel Aviv University

Focal Technology Area: Nanomedicines for Personalized Theranostics


Tel-Aviv University

Headed by: Prof. Dan Peer

Advances in nano-scale science and bio-nano-engineering are revolutionizing our understanding and ability to manipulate complex biological processes, as well as the way health care is administered. New approaches and innovations, collectively termed as Nanomedicine, are on the verge of improving disease prevention, detection, treatment and management.

The development of nanomedicines for theranostics (therapy and diagnostics) of diseases is driven by principles from diverse fields of science. Unlike conventional therapies , targeted nanomedicines offer more effective treatment with reduced adverse effects by supporting:
  1. Enhanced specificity in the delivery of large amounts of therapeutic or imaging payloads per recognition event;

  2. Delivery of multiple agents simultaneously, and;

  3. Overcoming biological barriers such as drug resistance.

In this project, we develop new theranostics platforms. In particular we address cancer, inflammation and cardiovascular diseases (all angiogenesis-dependent diseases) focusing on enhanced personalization of the treatment .


The Tel Aviv University FTA includes nine principal investigators from Tel Aviv University and three principal investigators from Ben-Gurion University of the Negev, The Hebrew University of Jerusalem and Bar-Ilan University. We are utilizing our members’ unique capabilities and developing several strategies to target specific cell types in a personalized manner, i.e. by sequencing patients' samples and designing specific nanocarriers with targeting agents appropriate to the specific patient as well as designing personalized therapeutic payloads using RNA interference (RNAi) strategy.   

These platforms are designed and synthesized from different biocompatible materials (lipid based, soluble polymer based, dendrimers, inorganic nanoparticles and polysaccharides based) with the ability to carry a variety of therapeutic and imaging agents that can manipulate cellular functions with high specificity and in a safe manner.

The consortium is orchestrated by the director, Prof. Dan Peer, the vice director, Prof. Ronit Satchi-Fainaro and the technical manager, Dr. Inbal Halevy .  Prof. Dan Peer is coordinating the work by joint group meetings, scientific advisory board (SAB) meetings headed by Prof. Robert Langer from MIT, annually and intermediates scientific reports, through the website and databases.